Selank: Anxiolytic and Nootropic Peptide Research Guide — Mechanism, Evidence and Protocols

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (IMG RAS) in Moscow. It is structurally based on tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide fragment of immunoglobulin G (IgG) with known immunomodulatory properties, extended with a Pro-Gly-Pro tripeptide stabiliser that significantly increases the metabolic half-life of the molecule.

Selank received registration as a pharmaceutical agent in Russia and Ukraine (registered as a nasal spray under the trade name Selank), where it has been in clinical use for anxiety disorders. In Western research contexts, it is studied as a research-grade peptide for its nootropic, anxiolytic, and immunomodulatory properties.

Selank at a glanceSequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids) · MW: ~751 Da · Parent peptide: tuftsin (Thr-Lys-Pro-Arg) · Developer: Institute of Molecular Genetics, Russian Academy of Sciences · Administration: nasal spray (registered) or subcutaneous injection (research)

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide produced by enzymatic cleavage of the Fc region of IgG. Discovered in 1970 by Victor Najjar at Tufts University, its endogenous functions include phagocytosis stimulation, NK cell activation, antinociceptive effects, and direct CNS activity via interaction with enkephalinase.

Tuftsin has a very short plasma half-life (~2 minutes) due to rapid enzymatic degradation. Selank's Pro-Gly-Pro extension significantly increases its resistance to degradation while preserving and amplifying its CNS-active properties.

Selank's mechanism involves several converging systems:

1. Enkephalinase Inhibition

Selank inhibits enkephalinase — the enzyme responsible for degrading met-enkephalin and leu-enkephalin (endogenous opioid pentapeptides). By slowing enkephalin breakdown, Selank elevates endogenous opioid peptide levels at synaptic clefts, contributing to anxiolytic effects without direct opioid receptor agonism. This mechanism explains why it does not produce physical dependence.

2. GABAergic Modulation

Electrophysiological studies have shown Selank modulates GABA-A receptor function as a positive allosteric modulator — similar in direction to benzodiazepines but with different binding site and weaker intrinsic efficacy, explaining anxiolytic effect without the full sedative profile.

3. BDNF and Neurotrophin Upregulation

Multiple rodent studies show Selank administration increases BDNF expression in hippocampal tissue — critical for synaptic plasticity, long-term potentiation (LTP), and memory consolidation. This underlies Selank's nootropic effects, particularly improvements in working memory under stress conditions.

4. Serotonin Modulation

Selank increases serotonin (5-HT) turnover in the frontal cortex and limbic system, contributing to mood stabilisation and differentiating its mechanism from pure GABAergic compounds.

5. IL-6 / Immune Signalling

Selank normalises IL-6 and related cytokine dysregulation under stress conditions — bidirectional immunomodulation consistent with its tuftsin origin.

The core of Selank's research value is its anxiolytic profile without the key adverse effects of benzodiazepines.

Animal anxiety models:

• Elevated plus-maze (EPM) — Selank-treated rodents showed increased open-arm time comparable to diazepam-treated controls, without locomotor depression (sedation marker) seen with diazepam
• Open field test — anxiolytic effects without reducing overall locomotor activity, in contrast to diazepam
• Chronic stress paradigms — normalised anxiety behaviour and corticosterone levels more rapidly than untreated controls

Selank's nootropic profile is secondary to its anxiolytic profile but well-supported in the preclinical literature:

• Working memory — Morris water maze and radial arm maze studies showed improved spatial learning and memory retention, particularly in stress-exposed groups where corticosterone elevation normally impairs hippocampal consolidation
• BDNF-mediated plasticity — hippocampal BDNF upregulation mechanistically links to LTP and memory formation. Selank-enhanced BDNF provides a pharmacological model for studying stress-impaired memory consolidation
• Attention and concentration — limited human data from Russian clinical trials reported improvements in concentration and processing speed in patients with anxiety-cognitive overlap
• Neuroprotection against glutamate toxicity — in vitro studies showed Selank reduced neuronal cell death from excitotoxic glutamate exposure

Selank's tuftsin origin gives it a distinct immunomodulatory dimension absent in most nootropic peptides:

• T-lymphocyte activity — consistent with tuftsin's known immune functions, Selank influences T-cell activity and has been studied in stress-induced immunosuppression models
• Cytokine normalisation — under stress conditions, Selank normalises cytokine dysregulation (particularly IL-6) without generating a primary immune activation at baseline — bidirectional immunomodulation rather than immunostimulant or immunosuppressant

Selank holds pharmaceutical registration in Russia and Ukraine for generalised anxiety disorder, neurasthenia, and adjustment disorders with anxious mood. The registered formulation is a 0.15% intranasal spray (~300–400 µg per dose). Russian clinical trial data supporting registration included randomised trials against placebo and active comparators (buspirone, phenazepam) — published in Russian-language literature and not yet replicated in independent Western RCTs as of 2026.

The intranasal route exploits olfactory epithelial axonal projections to the olfactory bulb and limbic system — bypassing the BBB for at least a portion of the dose, enabling rapid CNS effects relevant to anxiety and cognition research.

See the Semax Research Guide for the complementary profile.

RetaLABS Selank is supplied as lyophilised powder.

• Add bacteriostatic water slowly along the vial wall; gently swirl until dissolved — do not shake
• Typical research concentration: 0.5–1mg/mL
• Store lyophilised at −20°C, protected from light
• Reconstituted: 2–8°C, use within 4 weeks. Avoid freeze-thaw cycles.

See the Peptide Reconstitution & Storage Guide for protocol notes.

What is Selank primarily used for in research?

Selank is primarily researched as an anxiolytic compound with a favourable safety profile compared to benzodiazepines. Key research applications include anxiety and stress models, BDNF/neurotrophin research, nootropic/cognitive studies, and immunomodulation. Its anxiolysis without sedation or dependence potential makes it a useful reference compound in anxiety pharmacology.

How does Selank differ from benzodiazepines?

Selank produces anxiolytic effects without sedation, cognitive impairment, or physical dependence. It acts through enkephalinase inhibition, GABA-A modulation, and BDNF upregulation rather than potent GABA-A positive allosteric modulation.

What is the relationship between Selank and tuftsin?

Selank is a synthetic analogue of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide derived from IgG with immunomodulatory and CNS-active properties. Tuftsin has a ~2 min plasma half-life; Selank's Pro-Gly-Pro extension significantly increases metabolic stability while amplifying CNS-active properties.

Can Selank and Semax be used together in research?

Yes — their profiles are complementary. Selank is primarily anxiolytic with mild cognitive support; Semax is primarily neuroprotective with strong BDNF effects. Researchers studying stress-impaired cognition often use both in combination protocols. No adverse interaction data exists in preclinical studies.

RetaLABS Selank is sourced from manufacturers providing a Certificate of Analysis (COA) with each batch. All products are for laboratory research use only.

For the complementary nootropic profile, see the Semax Research Guide. For the broader nootropic landscape, see the Nootropic Peptides Guide. For the Australian regulatory framework, see the Research Peptides Legal Guide.